Nature reviews. Clinical oncology 2024 Dec
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?
Related Questions
The approval for vorasidenib was granted for low-grade astrocytomas, but under certain conditions, it can also be recommended for, for example, anapla...
New comment by Radiation Oncologist at Renaissance Institute of Precision Oncology & Radiosurgery ( September 4, 2025)
As an example of a very troubling trend, I am currently caring for a young patient who saw the division head of neuro-oncology at a major cancer center with grade 3 IDH-mutant...